The FDA has approved a blood-based test to help detect high-grade prostate tumors. The test is intended to aid in the diagnosis of prostate cancer, particularly in cases with elevated PSA levels. Reports vary on the specific details of the test, but it appears to be a diagnostic tool to help stratify the risk of prostate cancer and guide biopsy decisions.